Developing inhibitors of an essential histidine kinase in Staphylococcus aureus

开发金黄色葡萄球菌必需组氨酸激酶抑制剂

• 批准号: nhmrc : 1010776
• 负责人: Prof Glenn King
• 金额: $ 38.56万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-inhibitors-an-staphylococcus-aureus/109529
• 关键词: Developing; inhibitors; essential; histidine; kinase

Staphylococcus aureus (Golden staph) has been termed a "superbug" because of its persistent ability to acquire resistance to a wide range of antibiotics. Once considered primarily a hospital-acquired pathogen, many patients are now being infected with antibiotic-resistant Golden staph outside of hospitals. The primary aim of this research program is to develop new antibiotics to treat antibiotic-resistant strains of Staphylococcus aureus and related pathogens.

金黄色葡萄球菌（金黄色葡萄球菌）被称为“超级细菌”，因为它具有对广泛抗生素产生耐药性的持久能力。曾经被认为主要是医院获得性病原体，现在许多患者在医院外感染了耐药性金黄色葡萄球菌。该研究计划的主要目的是开发新的抗生素来治疗金黄色葡萄球菌和相关病原体的耐药性菌株。